 |
AlloVir
Last updated: May 06, 2024
David Hallal, CEO
Country: USA | Funding: $435M (+)
Website: https://www.allovir.com
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
Website: https://www.allovir.com
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
